The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics has introduced ALLO-329, an investigational allogeneic CAR T cell therapy designed for autoimmune disease treatment. The therapy leverages proprietary Dagger technology, aiming to reduce or eliminate the need for lymphodepletion in patients undergoing cell therapy.
This approach could represent a significant advancement in the management of autoimmune conditions by potentially minimizing side effects associated with standard lymphodepletion regimens. ALLO-329 remains under investigation and is not yet approved for commercial use. Further details about the clinical progress and potential impact of ALLO-329 can be found on Allogene Therapeutics' official site.
Allogene Therapeutics recently set its Q1 2026 earnings call for May 13 to provide updates on CAR-T and cell therapy development, according to a company announcement. The company’s CTO Ben Beneski is scheduled to join an industry panel on advancing next-generation cell-based therapies at a leading event, as reported in a previous update. These events reflect ongoing efforts by Allogene to advance its cell therapy pipeline.